Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345010 | 0.90 | EPHX2 (0.36) | CYP4F2CYP4A11SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL23345230 | 0.80 | CYP4F2 (0.40) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL23344999 | 0.73 | CYP1A2 (0.39) | CYP4F2CYP4A11SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL21997013 | 0.73 | NR1H2 (0.34) | — | |
| SCHEMBL21997014 | 0.73 | NR1H2 (0.34) | — | |
| SCHEMBL24597128 | 0.71 | EPHX2 (0.42) | SMN1; SMN2EPHX2ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL23995666 | 0.71 | CYP1A2 (0.38) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL23345258 | 0.69 | CYP2D6 (0.39) | CYP4F2CYP4A11ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL23344765 | 0.69 | SMN1; SMN2 (0.41) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL23345220 | 0.67 | CYP4F2 (0.42) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | CYP4F2 586/4885CYP4A11 305/4885SMN1; SMN2 375/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP4F2 951/4885CYP4A11 696/4885SMN1; SMN2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.